Search alternatives:
"motet" » "lotet", "mote", "monet"
"motets" » "lotets", "motes", "monets"
"votes" » "vote"

1
Published 2015
Canadian Agency for Drugs and Technologies in Health
... noted. Thus, this update will expand on the work of the previous CADTH reports to further investigate...

2
Published 2015
Canadian Agency for Drugs and Technologies in Health
... noted. Thus, this update will expand on the work of the previous CADTH reports to further investigate...

3
Published 2020
Canadian Agency for Drugs and Technologies in Health
... component. The CADTH clinical review also noted uncertainty in the meaningfulness of the observed...

4
Published 2015
Canadian Agency for Drugs and Technologies in Health
.... Of note, the Canadian Drug Expert Committee recommendations for the existing DPP-4 inhibitors have...

5
Published 2015
Canadian Agency for Drugs and Technologies in Health
.... Of note, the Canadian Drug Expert Committee recommendations for the existing DPP-4 inhibitors have...

6
Published 2014
Canadian Agency for Drugs and Technologies in Health
...). As the Canadian Biosafety Standards and Guidelines note: "Using the wrong respirator or misusing one can...

7
by Singh, Kavita, McCormack, Suzanne
Published 2018
CADTH
.... Rituximab was given a positive recommendation, however the Committee noted that the evidence for repeated...

8
Published 2018
Canadian Agency for Drugs and Technologies in Health
... of individual P2Y12 inhibitors. Of note, the patient subgroups were selected based on the clinical components...

9
Published 2018
Canadian Agency for Drugs and Technologies in Health
... of individual P2Y12 inhibitors. Of note, the patient subgroups were selected based on the clinical components...

10
by Singh, Kavita, McCormack, Suzanne
Published 2018
CADTH
.... Rituximab was given a positive recommendation, however the Committee noted that the evidence for repeated...

11
Published 2019
Canadian Agency for Drugs and Technologies in Health
... is ongoing about the optimal duration of DAPT. Of note, patient characteristics may be an important factor...

12
Published 2019
Canadian Agency for Drugs and Technologies in Health
... is ongoing about the optimal duration of DAPT. Of note, patient characteristics may be an important factor...

13
Published 2021
Canadian Agency for Drugs and Technologies in Health
... at a WTP threshold of $50,000 per QALY. It should be noted there is significant uncertainty around...

14
Published 2015
Canadian Agency for Drugs and Technologies in Health
... criteria be modified to reflect the indication under review. Of note, Canadian Expert Drug Advisory...

15
Published 2021
CADTH

16
by Cowling, Tara, Jones, Sarah
Published 2017
Canadian Agency for Drugs and Technologies in Health
..., many of them noting the limitations of the current literature. For instance, some authors suggest using...

17
Published 2016
Canadian Agency for Drugs and Technologies in Health
...) noted that at the time of the CDR review, there were no direct comparisons of denosumab with other...

18
by Cowling, Tara, Jones, Sarah
Published 2017
Canadian Agency for Drugs and Technologies in Health
..., many of them noting the limitations of the current literature. For instance, some authors suggest using...

19
Published 2015
Canadian Agency for Drugs and Technologies in Health

20
Published 2021
Canadian Agency for Drugs and Technologies in Health